Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Clovis Oncology Inc
(NQ:
CLVS
)
N/A
UNCHANGED
Last Price
Updated: 4:00 PM EST, Dec 20, 2022
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Clovis Oncology Inc
< Previous
1
2
Next >
Clovis Oncology and ITM Announce Lutetium-177 Clinical Supply Agreement
October 19, 2021
From
Clovis Oncology, Inc.
Via
Business Wire
Pan-Cancer Analysis Suggests Fibroblast Activation Protein (FAP) is an Attractive Target for Peptide-Targeted Radionuclide Therapy with FAP-2286
October 07, 2021
From
Clovis Oncology, Inc.
Via
Business Wire
Clovis Oncology Retires Remaining 2021 Notes and Raises Additional Capital through its ATM Equity Offering Program
September 20, 2021
From
Clovis Oncology, Inc.
Via
Business Wire
Global Radiotherapy Market Expected To Reach $7.3 Billion with a CAGR Of 4.2% By 2026
September 20, 2021
Via
FinancialNewsMedia
Clovis Oncology Announces Renewal of At-The-Market Equity Offering Program
August 16, 2021
From
Clovis Oncology, Inc.
Via
Business Wire
Clovis Oncology Announces Second Quarter 2021 Operating Results
August 04, 2021
From
Clovis Oncology, Inc.
Via
Business Wire
Clovis Oncology to Announce Second Quarter 2021 Financial Results and Host Webcast Conference Call on August 4
July 21, 2021
From
Clovis Oncology, Inc.
Via
Business Wire
Clovis Oncology Appoints Dr. Ronit Simantov to its Board of Directors
July 12, 2021
From
Clovis Oncology, Inc.
Via
Business Wire
Initial Clinical Experience of FAP-2286 in Independent Named Patient Use Published in The Journal of Nuclear Medicine
June 28, 2021
From
Clovis Oncology, Inc.
Via
Business Wire
Global Glioblastoma Multiforme (GBM) Treatment Market Could Reach Nearly $1.8 Billion By 2027
June 29, 2021
Via
FinancialNewsMedia
Clovis Oncology Announces LuMIERE Clinical Trial Evaluating Novel Peptide-Targeted Radionuclide Therapy FAP-2286 Now Open for Enrollment
June 23, 2021
From
Clovis Oncology, Inc.
Via
Business Wire
Clovis Oncology Announces Partial Adjournment of Annual Meeting of Stockholders
June 10, 2021
From
Clovis Oncology, Inc.
Via
Business Wire
Clovis Oncology Highlights Rubraca® (rucaparib) and Lucitanib Data at 2021 ASCO Annual Meeting
May 19, 2021
From
Clovis Oncology, Inc.
Via
Business Wire
Clovis Oncology Announces At-The-Market Equity Offering Program
May 17, 2021
From
Clovis Oncology, Inc.
Via
Business Wire
Clovis Oncology Announces First Quarter 2021 Operating Results
May 05, 2021
From
Clovis Oncology, Inc.
Via
Business Wire
Clovis Oncology to Present at the Bank of America 2021 Health Care Conference
April 28, 2021
From
Clovis Oncology, Inc.
Via
Business Wire
Clovis Oncology to Announce First Quarter 2021 Financial Results and Host Webcast Conference Call on May 5
April 21, 2021
From
Clovis Oncology, Inc.
Via
Business Wire
Clovis Oncology Highlights Rubraca® (rucaparib) Clinical Data at AACR Virtual Annual Meeting 2021
April 10, 2021
From
Clovis Oncology, Inc.
Via
Business Wire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.